Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 25-Apr-18 4:58 PM View:  | Harrelson Lori R. Vice President of Finance | Argos Therapeutics Inc (ARGS) | 25-Apr-18 | Disposition | 22,629 | -- | -- | (66%) 34.41K to 11.78K | |
| 25-Apr-18 4:59 PM View: | Abbey Jeffrey D Chief Executive Officer Director | Argos Therapeutics Inc (ARGS) | 25-Apr-18 | Disposition | 67,887 | -- | -- | (73%) 93.34K to 25.45K | |
| 25-Apr-18 4:57 PM View: | Nicolette Charles A. CSO and Vice President of R&D | Argos Therapeutics Inc (ARGS) | 25-Apr-18 | Disposition | 27,150 | -- | -- | (58%) 47.21K to 20.06K | |
| 25-Apr-18 4:58 PM View: | Katz Richard D Vice President and CFO | Argos Therapeutics Inc (ARGS) | 25-Apr-18 | Disposition | 22,629 | -- | -- | (70%) 32.33K to 9.7K | |
| 30-Mar-18 5:13 PM View: | Nicolette Charles A. CSO and Vice President of R&D | Argos Therapeutics Inc (ARGS) | 28-Mar-18 | Grant | 27,150 | -- | -- | 135% 20.06K to 47.21K | |
| 02-Apr-18 9:48 AM View: | Katz Richard D Vice President and CFO | Argos Therapeutics Inc (ARGS) | 28-Mar-18 | Grant | 22,629 | -- | -- | 233% 9.7K to 32.33K | |
| 30-Mar-18 5:14 PM View: | Harrelson Lori R. Vice President of Finance | Argos Therapeutics Inc (ARGS) | 28-Mar-18 | Grant | 22,629 | -- | -- | 192% 11.78K to 34.41K | |
| 30-Mar-18 5:12 PM View: | Abbey Jeffrey D Chief Executive Officer Director | Argos Therapeutics Inc (ARGS) | 28-Mar-18 | Grant | 67,887 | -- | -- | 267% 25.45K to 93.34K | |
| 12-Jan-18 1:55 PM View: | Nicolette Charles A. CSO and Vice President of R&D | Argos Therapeutics Inc (ARGS) | 09-Jan-18 | Market Sale (Planned) | 100,250 | $0.16 | $16,501.20 | (20%) 500.24K to 399.99K | 92% |
| 12-Jan-18 1:41 PM View: | Katz Richard D Vice President and CFO | Argos Therapeutics Inc (ARGS) | 09-Jan-18 | Market Sale (Planned) | 104,435 | $0.16 | $17,200.40 | (35%) 298.39K to 193.96K | 92% |
| 12-Jan-18 2:01 PM View: | Harrelson Lori R. Vice President of Finance | Argos Therapeutics Inc (ARGS) | 09-Jan-18 | Market Sale (Planned) | 64,329 | $0.16 | $10,595.00 | (22%) 295.31K to 230.98K | 92% |
| 12-Jan-18 1:48 PM View: | Abbey Jeffrey D President, CEO Director | Argos Therapeutics Inc (ARGS) | 09-Jan-18 | Market Sale (Planned) | 124,987 | $0.16 | $20,572.90 | (20%) 635.03K to 510.05K | 92% |
| 05-Jan-18 11:46 AM View: | Abbey Jeffrey D President, CEO Director | Argos Therapeutics Inc (ARGS) | 03-Jan-18 | Market Sale (Planned) | 114,702 | $0.16 | $18,719.40 | (15%) 749.74K to 635.03K | 99% |
| 05-Jan-18 12:12 PM View: | Katz Richard D Vice President and CFO | Argos Therapeutics Inc (ARGS) | 03-Jan-18 | Market Sale (Planned) | 101,228 | $0.16 | $16,540.70 | (25%) 399.62K to 298.39K | 99% |
| 05-Jan-18 11:56 AM View: | Harrelson Lori R. Vice President of Finance | Argos Therapeutics Inc (ARGS) | 03-Jan-18 | Market Sale (Planned) | 59,072 | $0.16 | $9,658.27 | (17%) 354.38K to 295.31K | 99% |
| 05-Jan-18 12:27 PM View: | Abbey Jeffrey D President, CEO Director | Argos Therapeutics Inc (ARGS) | 03-Jan-18 | Market Sale (Planned) Duplicate | 114,702 | $0.16 | $18,719.40 | (15%) 749.74K to 635.03K | 99% |
| 05-Jan-18 12:04 PM View: | Nicolette Charles A. CSO and Vice President of R&D | Argos Therapeutics Inc (ARGS) | 03-Jan-18 | Market Sale (Planned) | 92,001 | $0.16 | $15,060.60 | (16%) 592.24K to 500.24K | 99% |
| 02-Nov-17 3:48 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 31-Oct-17 | Disposition (other) | 99,495 | $795.96 | $79,194,000.00 | (< 1%) 13.24M to 13.14M | |
| 31-Aug-17 6:48 PM View: | Nicolette Charles A. Chief Science Officer | Argos Therapeutics Inc (ARGS) | 30-Aug-17 | Grant | 499,445 | -- | -- | 538% 92.8K to 592.24K | |
| 31-Aug-17 6:58 PM View: | Katz Richard D VP and Chief Financial Officer | Argos Therapeutics Inc (ARGS) | 30-Aug-17 | Grant | 395,664 | -- | -- | 9997% 3.96K to 399.62K | |
| 31-Aug-17 7:04 PM View: | Harrelson Lori R. Vice President of Finance | Argos Therapeutics Inc (ARGS) | 30-Aug-17 | Grant | 320,683 | -- | -- | 952% 33.7K to 354.38K | |
| 31-Aug-17 6:29 PM View: | Abbey Jeffrey D Chief Executive Officer Director | Argos Therapeutics Inc (ARGS) | 30-Aug-17 | Grant | 622,685 | -- | -- | 490% 127.05K to 749.74K | |
| 23-Jan-17 3:57 PM View: | Harrelson Lori R. Vice President Finance | Argos Therapeutics Inc (ARGS) | 20-Jan-17 | Grant | 3,694 | -- | -- | 12% 30.0K to 33.7K | |
| 23-Jan-17 3:23 PM View: | Allen Lee F Md Phd Chief Medical Officer | Argos Therapeutics Inc (ARGS) | 19-Jan-17 | Grant | 7,378 | -- | -- | 100% 0 to 7.38K | |
| 23-Jan-17 3:09 PM View: | Abbey Jeffrey D Chief Executive Officer Director | Argos Therapeutics Inc (ARGS) | 19-Jan-17 | Grant | 17,430 | -- | -- | 16% 109.62K to 127.05K | |
| 23-Jan-17 3:38 PM View: | Winterbottom Joan Chief Human Resources Officer | Argos Therapeutics Inc (ARGS) | 19-Jan-17 | Grant | 4,464 | -- | -- | 10% 42.78K to 47.25K | |
| 23-Jan-17 3:32 PM View: | Katz Richard D VP & Chief Financial Officer | Argos Therapeutics Inc (ARGS) | 19-Jan-17 | Grant | 3,958 | -- | -- | 100% 0 to 3.96K | |
| 23-Jan-17 3:03 PM View: | Nicolette Charles A. Chief Science Officer | Argos Therapeutics Inc (ARGS) | 19-Jan-17 | Grant | 16,753 | -- | -- | 22% 76.04K to 92.8K | |
| 04-Jan-17 11:28 AM View: | Mtibelishvily Irackly Director | Argos Therapeutics Inc (ARGS) | 31-Dec-16 | Grant | 395 | -- | -- | 3% 14.5K to 14.89K | |
| 04-Jan-17 11:41 AM View: | Carey Robert Director | Argos Therapeutics Inc (ARGS) | 31-Dec-16 | Grant | 2,351 | -- | -- | 40% 5.86K to 8.21K | |
| 04-Jan-17 11:31 AM View: | Krol Igor Director | Argos Therapeutics Inc (ARGS) | 31-Dec-16 | Grant | 1,785 | -- | -- | 85% 2.09K to 3.87K | |
| 04-Jan-17 11:21 AM View: | Birner Hubert Director | Argos Therapeutics Inc (ARGS) | 31-Dec-16 | Grant | 3,571 | -- | -- | 39% 9.11K to 12.68K | |
| 04-Jan-17 11:38 AM View: | Snyderman Ralph Director | Argos Therapeutics Inc (ARGS) | 31-Dec-16 | Grant | 573 | -- | -- | 100% 0 to 0.57K | |
| 13-Oct-16 4:48 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 07-Oct-16 | Market Purchase | 21,000 | $4.73 | $99,330.00 | < 1% 13.22M to 13.24M | (100%) |
| 13-Oct-16 4:48 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 06-Oct-16 | Market Purchase | 2,640 | $4.81 | $12,698.40 | < 1% 13.22M to 13.22M | (100%) |
| 13-Oct-16 4:48 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 05-Oct-16 | Market Purchase | 900 | $4.85 | $4,365.00 | < 1% 13.22M to 13.22M | (100%) |
| 13-Oct-16 4:48 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 04-Oct-16 | Market Purchase | 7,164 | $4.69 | $33,599.20 | < 1% 13.21M to 13.22M | (100%) |
| 04-Oct-16 4:12 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 03-Oct-16 | Market Purchase | 11,308 | $4.70 | $53,147.60 | < 1% 13.2M to 13.21M | (100%) |
| 04-Oct-16 4:12 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 30-Sep-16 | Market Purchase | 30,232 | $4.71 | $142,393.00 | < 1% 13.17M to 13.2M | (100%) |
| 03-Oct-16 1:31 PM View: | Carey Robert Director | Argos Therapeutics Inc (ARGS) | 30-Sep-16 | Grant | 2,263 | -- | -- | 63% 3.59K to 5.86K | |
| 03-Oct-16 11:23 AM View: | Krol Igor Director | Argos Therapeutics Inc (ARGS) | 30-Sep-16 | Grant | 1,760 | -- | -- | 535% 0.33K to 2.09K | |
| 03-Oct-16 11:14 AM View: | Birner Hubert Director | Argos Therapeutics Inc (ARGS) | 30-Sep-16 | Grant | 3,521 | -- | -- | 63% 5.59K to 9.11K | |
| 03-Oct-16 11:18 AM View: | Petrov Andrei Vladimirovich Director | Argos Therapeutics Inc (ARGS) | 30-Sep-16 | Grant | 2,137 | -- | -- | 25% 8.39K to 10.53K | |
| 03-Oct-16 11:28 AM View: | van Deventer Sander Director 10% Owner | Argos Therapeutics Inc (ARGS) | 30-Sep-16 | Grant | 2,263 | -- | -- | 81% 2.79K to 5.06K | |
| 03-Oct-16 11:36 AM View: | van Holle Philippe Marie Ma... Director | Argos Therapeutics Inc (ARGS) | 30-Sep-16 | Grant | 2,263 | -- | -- | 5% 48.69K to 50.95K | |
| 30-Sep-16 4:20 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 29-Sep-16 | Market Purchase | 15,100 | $4.60 | $69,460.00 | < 1% 13.15M to 13.17M | (100%) |
| 30-Sep-16 4:20 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 28-Sep-16 | Market Purchase | 28,518 | $4.54 | $129,472.00 | < 1% 13.13M to 13.15M | (100%) |
| 21-Sep-16 7:50 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 20-Sep-16 | Market Purchase | 41,259 | $4.77 | $196,805.00 | < 1% 13.08M to 13.13M | (100%) |
| 21-Sep-16 7:50 PM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 19-Sep-16 | Market Purchase | 5,580 | $4.76 | $26,560.80 | < 1% 13.08M to 13.08M | (100%) |
| 20-Sep-16 8:36 AM View: | Pharmstandard International... 10% Owner | Argos Therapeutics Inc (ARGS) | 16-Sep-16 | Market Purchase | 36,632 | $4.78 | $175,101.00 | < 1% 13.04M to 13.08M | (100%) |
